Real-Time PCR for Diagnosis of Oculoglandular Tularemia by Maurin, Max et al.
LETTERS




To the Editor: Oculoglandular 
tularemia accounts for 3%–5% of all 
diagnosed tularemia cases (1). We re-
port the diagnosis of this disease in 2 
patients in France by real-time PCR. 
Patient A, a 43-year-old woman, 
was referred in October 2006 to the 
infectious disease department of Auch 
Hospital (Auch, France). She had a 
fever (39°C) and severe conjunctivi-
tis of the right eye that had evolved 
over 2 weeks despite administration 
of amoxicillin/clavulanate. The pa-
tient lived in a rural area endemic for 
tularemia and had regular contact with 
dogs and ring doves. She remembered 
harvesting mushrooms in a nearby for-
est a few days before onset of clini-
cal symptoms. Physical examination 
showed a hyperemic and painful right 
conjunctiva, enlarged (0.5–1.5 cm in 
diameter) and tender preauricular and 
submandibular lymph nodes, and cel-
lulitis of the right hemiface. Her con-
dition rapidly improved after she re-
ceived doxycycline and gentamicin.
Patient B, a 42-year-old woman, 
was referred in October 2008 to the 
infectious disease department of Dijon 
University Hospital (Dijon, France) 
for intermittent fever (38.5°C) and 
swollen left-sided pretragal and cervi-
cal lymph nodes, which had evolved 
for 3 weeks despite administration of 
amoxicillin, followed by pristinamy-
cin and prednisone, and ciproﬂ  oxacin 
for 7 days. The patient remembered 
being scratched on the left hand by her 
dog several weeks earlier; the scratch 
healed spontaneously. She had re-
cently walked in a nearby forest that 
was endemic for tularemia. Physical 
examination showed enlarged (2–3 
cm in diameter), tender lymph nodes 
and bilateral conjunctivitis. Her con-
dition improved after doxycycline 
therapy, but the pretragal lymph nodes 
were removed surgically in late No-
vember 2008 because of suppuration 
and necrosis. Oﬂ   oxacin was admin-
istered until January 2009 because of 
persistence of inﬂ   ammation in cer-
vical lymph nodes and suppuration 
with skin ﬁ  stulization in the pretragal 
region.
Diagnostic investigations (Table) 
conducted at Grenoble University 
Hospital included serologic tests (mi-
croagglutination and indirect immu-
noﬂ  uorescent antibody assay by using 
locally prepared Francisella tularen-
sis subsp. holarctica antigen), culture, 
and 2 real-time PCRs. These PCRs 
were speciﬁ   c for insertion sequence 
ISFtu2 or the Tul4 protein–encoding 
gene of Francisella sp. and used pre-
viously described primers, probes, 
an ampliﬁ   cation protocol (2), and a 
LightCycler 2.0 apparatus (Roche, 
Meylan, France). We tested 5 μL of 
DNA extracted from clinical samples 
by using the QIAamp DNA Mini kit 
(QIAGEN, Hilden, Germany). Three 
negative controls (DNA-free water) 
and 1 positive control (DNA extracted 
from the F. tularensis subsp. holarc-
tica LVS strain) were used for each 
PCR.
Seroconversion was found be-
tween acute-phase and convalescent-
phase serum samples from both pa-
tients. A conjunctival cotton swab 
sample from patient A and pretragal 
lymph node suppuration and biopsy 
samples from patient B were posi-
tive for F.  tularensis by both real-
time PCRs. A Francisella sp. strain 
was isolated from the conjunctival 
discharge from patient A at Auch 
Hospital and Grenoble Hospital 
laboratories. Cultures were grown 
in a BioSafety Level 3 laboratory 
at Grenoble University Hospital be-
cause results of both PCRs were posi-
tive. Cultures of specimens from pa-
tient B were negative.
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Table. Characteristics of the 2 patients in the study and test results for tularemia, France* 
Characteristic Patient A  Patient B 
Age, y/sex  43/F 42/F
Blood leukocyte count at admission, cells/mm
3 21,600 4,000–10,000 
Blood granulocyte count at admission, cells/mm
3 17,900 2,000–8,000
C-reactive protein level at admission, mg/L  51 39
Serologic test results for Francisella tularensis
  First serum sample, d  6 16
  Microagglutination  titer  <20 <20
  Immunofluorescent  IgM  titer  <20 <20
  Immunofluorescent  IgG  titer  <20 <20
  Second serum sample, d   90 39
  Microagglutination  titer  80 160
  Immunofluorescent  IgM  titer  160 320
  Immunofluorescent  IgG  titer  160 320
Real-time PCR result for ISFtu2 and tul4, sample (cycle 
threshold for each test, respectively) 
Positive, conjunctival discharge 
(32.4 and 34.9) 
Positive, pretragal lymph node 
(22.3 and 24.5) 
Francisella sp. culture, sample  Positive, conjunctival discharge  Negative
Francisella subsp. identification  subsp. holarctica subsp. holarctica
*Ig, immunoglobulin. LETTERS
Both patients were infected with 
an F. tularensis subsp. holarctica strain. 
Infection was identiﬁ  ed by PCR am-
pliﬁ  cation and sequencing of the 16S 
rRNA gene (fD1 and rP2 primers) and 
the intergenic spacer region (FTitsFw 
5′-ACCACGGAGTGATTCATGAC
TG-3′ and FTitsRv 5′-TCTCAATTGA
TTTCTCTTCCTAAGG-3′ primers) 
from the strain isolated from patient A 
and directly from the lymph node bi-
opsy specimen from patient B.
Conjunctival inoculation of F. 
tularensis usually occurs by contact 
when a contaminated ﬁ  nger  comes 
into contact with the eyes, e.g., after 
handling of an infected animal or tick 
(3,4), but the source of infection often 
remains undetermined, as for our 2 pa-
tients. Symptoms are not speciﬁ  c and 
correspond to Parinaud oculoglandular 
syndrome (1). Reported complications 
include keratitis, occasional corneal 
perforation, and lymph node suppura-
tion; tonsillitis, cellulitis in nearby skin 
tissue, retinitis, erythema nodosum, 
and progression to systemic disease 
occur less frequently (3–7). A speciﬁ  c 
microbiologic diagnosis is needed for 
appropriate treatment because many 
microorganisms can cause Parinaud 
oculoglandular syndrome and clinical 
symptoms are not speciﬁ  c (1,8).
Fluoroquinolones are now con-
sidered ﬁ  rst-line treatment for tulare-
mia; β-lactam antimicrobial agents are 
not effective (9). Oculoglandular tula-
remia is a painful disease with a short 
incubation period (3–5 days), and re-
sults of serologic tests of acute-phase 
samples are often negative (1,9). Iso-
lation of F. tularensis is difﬁ  cult and 
hazardous to laboratory personnel 
(1,9). PCR-based techniques may en-
able a more rapid diagnosis (1,9,10). 
Heating clinical samples before test-
ing prevents laboratory-acquired in-
fections. 
We report the use of real-time 
PCR for detection of F. tularensis 
from a conjunctival swab specimen. 
Many clinical laboratories are now 
equipped with this technology. Trans-
port conditions of clinical samples 
(4°C, no transport medium, 24–48 h) 
are not restrictive. When compared 
with PCR, real-time PCR does not re-
quire post-PCR processing, enabling a 
faster turn-around time.
Oculoglandular tularemia is a rare 
but underestimated disease. Real-time 
PCR detection of F. tularensis DNA 
from conjunctival swab suspensions 
now provides a rapid, noninvasive, 
sensitive, and speciﬁ   c diagnosis of 
oculoglandular tularemia. This assay 
enables early establishment of spe-
ciﬁ   c antimicrobial drug therapy and 
poses no risk of infection for labora-
tory staff.
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